Posted by Michael Wonder on 07 Mar 2023
PHARMAC funds two new treatments for lung cancer
7 March 2023 - PHARMAC has announced the funding of two new medicines - pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for people with locally advanced and metastatic non-small cell lung cancer who meet certain eligibility criteria.
“The announcements we have made today for these two immune checkpoint inhibitors and for also Trikafta for those with cystic fibrosis, take us to 39 new funding decisions this financial year (since 1 July 2022), covering 18 new treatments and widened access to 21 others” says Ms Williams.
